Inhibition of nuclear factor κB regresses cardiac hypertrophy by modulating the expression of extracellular matrix...

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Pathology

Background:

• Myocardial remodeling, characterized by dysfunctional myocardium, is central to cardiac hypertrophy (CH) and heart failure (HF).
• Reactive oxygen species (ROS) and nuclear factor-κB (NF-κB) activation drive extracellular matrix (ECM) deposition and fibrosis in cardiac remodeling.
• Pyrrolidine dithiocarbamate (PDTC) is an NF-κB inhibitor and antioxidant with potential therapeutic benefits.

Purpose of the Study:

• To investigate the role of NF-κB inhibition by PDTC in preventing maladaptive cardiac remodeling.
• To evaluate the therapeutic potential of PDTC in a mouse model of cardiac hypertrophy and heart failure.

Main Methods:

• Utilized a transgenic mouse model (Myo-Tg) with cardiac-specific myotrophin overexpression, leading to CH and HF.
• Administered PDTC to Myo-Tg mice to inhibit NF-κB and assess its effects on cardiac remodeling.
• Quantified profibrotic gene expression (collagen I, III, fibronectin) and measured cardiac mass, NF-κB activity, and cardiac function.

Main Results:

• Myo-Tg mice exhibited upregulation of profibrotic genes and increased NF-κB activity compared to wild-type controls.
• PDTC treatment significantly reduced cardiac mass, NF-κB activity, and profibrotic gene expression in Myo-Tg mice.
• PDTC administration led to improved cardiac function in the cardiac remodeling model.

Conclusions:

• Inhibition of NF-κB activation by PDTC effectively reduces cardiac remodeling and fibrosis.
• PDTC demonstrates therapeutic benefits in mitigating maladaptive cardiac remodeling and improving cardiac function.
• Highlights the critical role of the NF-κB pathway in cardiac remodeling and the potential of PDTC as a therapeutic agent.